BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 82.3% from a year ago
Short-term investments stood at $199.62M at the end of Q1 FY2026, up 82.3% from a year earlier and up 285.6% from the prior quarter.
Context
- Short-term investments amounted to 47.8% of total assets at the end of Q1 FY2026, down 25.3 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +82.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 51.77M USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.77M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +82.3% is the 3rd highest of 8, against a peer median of +3.1%.
- Short-term investments amounts to 47.8% of total assets for BBOT, versus a peer median of 27.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $890.67M USD | +842.8% | -9.0% | 86.2% | |
| Jun 2026 | $411.79M USD | +3.1% | -4.6% | 56.8% | |
| Aug 2026 | $328.01M USD | -6.4% | +12.2% | 27.4% | |
SEPNSepterna, Inc. | Sep 2026 | $311.48M USD | +101.8% | — | 50.3% |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $199.62M USD | +82.3% | — | 47.8% |
| Mar 2026 | CHF 157M CHF | +28.6% | — | 64.5% | |
| Mar 2026 | $37.99M USD | -84.3% | -41.7% | 11.5% | |
| Mar 2026 | $30.31M USD | -67.0% | -39.8% | 11.9% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BBOT) | — | +3.1% | -9.0% | 27.4% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.